International Journal of Science and Research Archive

eISSN: 2582-8185

Cross Ref DOI: 10.30574/ijsra

Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

Closing the Insight Gap: AI-orchestrated customer engagement in the life sciences industry

Sahar Sadri Mehrabani *

School of Science, The University of New South Wales, Sydney, Australia.

International Journal of Science and Research Archive, 2025, 15(03), 423-432

Publication history: Received on 26 April 2025; revised on 04 June 2025; accepted on 06 June 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.15.3.1740

Abstract

Artificial intelligence (AI) is reshaping the paradigm of customer engagement in the life sciences industry. This paper investigates how pharmaceutical organizations are evolving beyond legacy customer relationship management (CRM) systems toward AI-enabled platforms that facilitate real-time, personalized interactions with healthcare professionals (HCPs). By embedding advanced capabilities—such as next-best-action (NBA) engines, behavioral analytics, and dynamic journey orchestration—platforms including IQVIA OCE+, Salesforce Life Sciences Cloud, and Veeva Vault CRM are actively bridging the long-standing "insight gap" between data acquisition and actionable engagement.

The analysis is complemented by case studies from Sanofi, Novartis, and Pfizer, illustrating how AI is being operationalized across omnichannel marketing, field execution, and medical communication. These examples reveal measurable improvements in engagement relevance, salesforce productivity, and marketing return on investment (ROI). While challenges persist around data integration, ethical governance, and organizational readiness, the findings underscore AI's emerging role as a foundational enabler of scalable, insight-led engagement across the commercial functions of life sciences enterprises.

Keywords: Artificial intelligence; Customer engagement; CRM; Life sciences; Pharmaceutical marketing; Healthcare professionals; Omnichannel strategy; Insight gap

1. Introduction

In the evolving landscape of life sciences, customer engagement has become both a strategic imperative and a persistent challenge. While pharmaceutical companies now possess unprecedented volumes of data on healthcare professionals (HCPs)—generated through webinars, CRM systems, digital platforms, and field interactions—many continue to struggle with translating this information into meaningful, context-aware engagement. This disconnect, widely termed the "insight gap," represents one of the most significant barriers to commercial effectiveness in the sector [40] [2].

Despite ongoing digital transformation, engagement strategies often remain outdated in design and fragmented in execution. Systems built for compliance and reporting frequently fall short of supporting real-time, personalized communication [40]. This gap is further reflected in the sector's lagging Digital Quotient score (assesses a firm's digital maturity across strategy, capabilities, culture, and organization to benchmark digital readiness and identify areas for improvement), which sits well below that of industries like banking and insurance [3]. Pharmaceutical companies invest over $137 billion annually in sales and marketing, yet continue to face major inefficiencies due to high costs, access challenges, and poor CRM utilization [41].

* Corresponding author: Sahar Sadri Mehrabani

Emerging evidence suggests that this paradigm is shifting. Artificial intelligence (AI) has begun to reconfigure the architecture of customer engagement by enabling more dynamic, predictive, and personalized strategies. Integrated within modern CRM platforms, AI-powered capabilities—such as behavioral analytics, next-best-action recommendations, and real-time orchestration—are repositioning engagement from reactive contact to anticipatory relationship-building [4] [40]. McKinsey & Company estimates that these innovations could unlock $8–16 billion in annual commercial value, primarily through improved HCP responsiveness and a projected 10–15% gain in field team productivity [5].

This paper investigates how pharmaceutical organizations are leveraging AI to close the insight gap and reimagine customer engagement as a continuously adaptive, insight-led process. Drawing on real-world examples from Sanofi, Novartis, Pfizer, AstraZeneca, and GSK, it explores how AI-driven orchestration is not only enhancing the relevance and effectiveness of HCP engagement but also redefining the commercial playbook for the digital era.

2. Literature Review

2.1. The Strategic Limitations of Traditional Omnichannel Engagement

Understanding why traditional engagement strategies have failed is critical to appreciating the value of AI-orchestrated customer engagement. Historically, life sciences engagement was shaped by field-rep visits and sample drops, supported by CRM systems designed primarily for compliance tracking and call logging, rather than for enabling dynamic, relationship-based communication. These systems were structured around volume-driven KPIs like call frequency and territory coverage, offering limited insight into engagement quality or outcomes [10] [5].

As digital maturity increased and HCP expectations evolved, pharmaceutical companies began integrating omnichannel tools to diversify engagement. However, many early implementations were disjointed, with channels such as email, webinars, rep visits, and mobile apps operating as parallel, uncoordinated efforts rather than as parts of a unified strategy. This fragmentation limited impact and exposed infrastructural weaknesses. According to Graphite Digital, 77% of pharmaceutical executives admitted their omnichannel strategies had delivered limited success, largely due to siloed systems and weak data integration [2].

At the same time, customer expectations shifted significantly. HCPs now demand personalized, timely, and value-based interactions tailored to their clinical roles and digital fluency. Deloitte's pan-European HCP survey in 2024 revealed that 52% of HCPs actively seek more clinical data, 67% expect more disease awareness content, and 42% identify lack of contact with medical science liaisons (MSLs) as a barrier to value-based engagement [7]. These unmet needs signal a transition from broad outreach to deeper, more meaningful engagement.

To address this, companies are moving beyond static segmentation toward micro segmentation and behavioral personalization. According to IQVIA, life sciences firms must shift from push-based promotion to pull-based, preference-led engagement, enabling HCPs to access content on their terms [9]. This approach aligns with the expectations of digital-native HCPs who value autonomy, relevance, and on-demand access.

However, operational gaps remain. Graphite Digital (2024) reports that 64% of marketers still lack a journey-based engagement strategy, despite 88% using customer insights to guide decision-making [2]. This mismatch reflects a maturity gap: while customer-centric rhetoric has become widespread, many organizations have yet to build the infrastructure necessary for scalable, personalized engagement.

2.2. The Role of AI in Addressing Engagement Fragmentation

As life sciences organizations confront the limitations of fragmented omnichannel strategies and the maturity gap in delivering customer-centric engagement at scale, artificial intelligence (AI) has emerged as a powerful enabler of transformation. Building on the need for micro-segmentation and behavioral personalization outlined earlier, AI offers a pathway to operationalize these strategies through automation, real-time insights, and scalable decision-making [40].

AI is increasingly recognized not only as a tool for automation but as a foundational component of real-time, insight-led engagement. AI integrated CRM platforms illustrate this shift, integrating behavioral data and predictive algorithms to guide personalized HCP interactions across content, channel, and timing [11]. Recent advances also highlight the role of AI-driven chatbots in supporting these efforts—offering 24/7 virtual assistance to HCPs, answering inquiries, and disseminating pharmaceutical information in a more immediate, scalable manner [41].

Key AI-driven capabilities include:

- **Predictive Targeting** – Algorithms identify high-priority HCPs based on prescribing behavior and prior engagement [8].
- **Next-Best-Action (NBA) Engines** – These tools generate real-time engagement recommendations based on behavioral data [4].
- **Sentiment Analysis** – NLP **(**Natural Language Processing) is used to decode tone and emotional context in email or conversation data, allowing for more empathetic engagement [4].
- **Journey Orchestration** – Real-time triggers adapt each HCP's engagement path in response to digital signals, content consumption, and feedback [11].

These capabilities reposition CRM platforms as customer experience orchestration layers—capable of delivering consistent, contextualized interactions at scale. However, adoption alone is not sufficient. IQVIA [8] and Deloitte [7] emphasize that AI's potential is only fully realized when embedded directly into commercial operations, including field team workflows and omnichannel delivery. Without this integration, the insight gap persists. Moreover, ensuring human-like interaction quality—particularly in AI interfaces such as chatbots—is becoming essential to increase HCP trust, satisfaction, and adoption of digital engagement channels [41].

3. AI-Enabled CRM Platforms: Bridging Data and Execution in Customer Engagement

Efforts to modernize customer engagement in life sciences have revealed the structural limits of legacy CRM platforms. These systems were originally built for compliance documentation and activity tracking. As a result, they lack the flexibility and intelligence needed to support personalized, real-time interactions with healthcare professionals (HCPs) [8].

To address this, a new generation of AI-powered CRM solutions has emerged. These platforms enable life sciences companies to deliver orchestrated, insight-led engagement. They embed features such as predictive analytics, behavioral segmentation, and next-best-action engines into omnichannel workflows. This allows engagement to adjust continuously to each HCP's needs and preferences [9] [11].

Rather than automating outdated processes, these systems reshape engagement operations. The shift is from reactive outreach to proactive, customer-centric journeys.

This section highlights three CRM platforms leading this transformation:

- **IQVIA OCE+,** which scales orchestrated engagement with embedded AI [1];
- **Salesforce Life Sciences Cloud**, which integrates AI-driven insights across enterprise functions [12];
- **Veeva Vault CRM**, built to support field teams with real-time, compliant, and rep-centric tools [15].

3.1. IQVIA OCE+: Orchestrated Customer Engagement at Scale

IQVIA's Orchestrated Customer Engagement Plus (OCE+) platform exemplifies the transformation of CRM into an AI-powered orchestration layer that enables scalable, compliant, and insight-led HCP engagement. Designed specifically for life sciences, OCE+ integrates real-world data, embedded intelligence, and modular workflows to unify sales, marketing, and medical activities across digital and field channels [1].

3.1.1. Key Capabilities

- **Next Best Action (NBA) Engine:** OCE+ is powered by more than 35 transparent, self-optimizing machine learning algorithms that generate weekly recommendations for each HCP—covering content, timing, and preferred channel. These recommendations are dynamically refined based on engagement signals and behavioral insights [31].
- **Dynamic Segmentation and Predictive Targeting:** OCE+ continuously adapts customer targeting using EMR, Rx data, and behavior-based segmentation. Notably, IQVIA found that 40% of HCPs change segments every six months, yet many pharma companies update targeting lists only every 12–36 months. OCE+ closes this gap by enabling real-time targeting updates [31].

- **Cross-Channel Orchestration:** By integrating rep visits, virtual calls, email, and other touchpoints, OCE+ ensures that every HCP experience is contextually aligned and strategically sequenced [11].
- **Consent-Aware Personalization:** Compliance with GDPR, local privacy laws, and individual HCP preferences are embedded into the orchestration engine—allowing for personalized engagement at scale without sacrificing regulatory alignment [31].
- **Explainable ("Glass Box") AI:** Reps and managers can view the rationale behind each NBA recommendation, improving confidence and increasing field team adoption [31].

3.1.2. Commercial Impact and Strategic Transformation

OCE+ has been deployed across 106 brands in 19 markets, with over 6,000 field representatives using live recommendations in under five months [31].

Key business outcomes include

- A **4.9%** increase in total prescriptions (TRx) and a **6.5%** increase in new-to-brand prescriptions (NBRx) within four weeks of deployment [1].
- A projected ROI of 8:1, attributed to more efficient execution, enhanced HCP alignment, and reduced time from insight to action [1].
- Reps following NBA (Next Best Action) recommendations sent emails over 50% of the time, five times higher than in the control group—resulting in a **35%** uplift in sales performance [32].
- User adoption exceeded 80% by week four, with feedback highlighting improved decision support and lower administrative burden [1].
- Faster decision-making: One deployment reduced the time from content readiness to customer engagement from five weeks to just 48 hours, through daily AI-triggered alerts and action workflows [33].
- Faster campaign execution and content activation: Integrated brand, medical, and legal review workflows reduced time-to-market for promotional content, improving agility in omnichannel delivery [34].

By enabling data-orchestrated targeting, real-time engagement adjustments, and explainable AI-driven decision support, this platform exemplifies how AI and NBA capabilities can convert insight into value—accelerating time-to-impact, scaling personalization, and enhancing strategic alignment across the customer journey.

3.2. Salesforce Pharma CRM: Unified Intelligence for Customer Journeys

Salesforce's Pharma CRM—a module within the broader Life Sciences Cloud suite—marks a significant shift in how pharmaceutical companies orchestrate customer engagement. Built on Salesforce's Einstein 1 platform and integrated with real-time data and compliance-ready workflows, the solution leverages AI to deliver predictive, contextual, and personalized experiences to healthcare professionals (HCPs) across commercial, medical, and service teams. As the world's #1 AI CRM platform, Salesforce brings proven intelligence and scale to life sciences transformation. As of 2024, several core modules are already generally available, while HCP Engagement for Pharma is set for general availability in October 2025 [12].

3.2.1. Key Capabilities

- **AI-Driven Engagement with Einstein for Life Sciences:** The Einstein AI engine underpins key capabilities including predictive lead scoring, dynamic content recommendations, and automated email generation. It also supports productivity-enhancing features such as Knowledge Article Generation and Service Replies—equipping medical science liaisons and field teams with timely, compliant, and context-specific responses [13].
- **360° Unified HCP Profiles:** Salesforce Pharma CRM unifies data from clinical research, sales, medical, and digital interactions to generate a dynamic view of each HCP. These profiles include consent preferences, clinical behaviors, and channel usage, enabling personalization based on therapeutic relevance and preferred communication modalities [35].
- **Consent-Embedded Orchestration and Privacy Compliance:** GDPR, HIPAA1, and other regional compliance standards are embedded directly into CRM workflows, with built-in consent governance that ensures only pre-approved communications are delivered. Reps are guided to respect individual HCP permissions and audit trails are automatically generated [35].
- **Dynamic Journey Orchestration Across Teams:** The platform's Dynamic Journey Builder enables cross-functional orchestration of HCP engagement across physical and digital touchpoints. Einstein AI suggests the optimal timing, message, and channel—aligning medical, commercial, and field activities around unified engagement paths [35].

3.2.2. Real-World Impact and Outcomes

- **24%** Increase in Sales Team Productivity: According to Salesforce's FY26 datasheet, organizations deploying Life Sciences Cloud reported a 24% improvement in employee productivity. This was driven by unified content workflows, AI-powered automation, and integrated omnichannel orchestration [35].
- SI-BONE Case: Automating Commercial Workflows: One early adopter, SI-BONE, used Salesforce's platform to automate implant order processes, reducing manual entry and saving hours weekly. This enabled commercial teams to shift focus from repetitive tasks to innovation and HCP engagement. As noted by SI-BONE's Senior Business Systems Manager, the platform helped "spend more time innovating and less time on cumbersome, manual processes" [12].
- Improved Workflow Efficiency and AI Adoption: Pilot projects have demonstrated stronger AI adoption across commercial functions and faster internal content activation workflows, particularly through the integration of Einstein AI into medical, legal, and brand content approvals [13] [35].
- Strategic Implications: As pharmaceutical companies phase out legacy CRM systems in favor of intelligent, compliance-ready engagement platforms, Salesforce Pharma CRM stands out for its ability to integrate AI, CRM, and consent-based orchestration on a unified cloud infrastructure. With a growing base of adopters—including Takeda, which is using Pharma CRM to integrate AI agents into both medical and patient-facing operations—Salesforce is positioning its platform as a cornerstone of next-generation HCP engagement [14].

3.3. Veeva Vault CRM: Rep-Centric AI for Field Execution

Veeva Vault CRM is a next-generation customer engagement platform designed specifically for the pharmaceutical industry's commercial and medical field teams. Following Veeva's strategic separation from Salesforce, the company re-architected its CRM solution from the ground up to focus on rep productivity, seamless omnichannel execution, and integrated artificial intelligence. In May 2023, Veeva officially announced the launch of Veeva AI, a domain-specific AI architecture embedded across Vault CRM and other commercial applications. The first release of Veeva AI in Vault CRM is scheduled for general availability in December 2025 [15].

3.3.1. Key Capabilities

- **AI-Embedded CRM Execution with CRM Bot:** At the core of Veeva's AI strategy is the CRM Bot, a GenAI assistant integrated into Vault CRM to deliver context-aware recommendations at the point of execution. Built using compliant, industry-specific language models, CRM Bot will provide field reps with dynamic guidance on next-best actions, content selection, and account planning—reducing cognitive load and enabling smarter, faster decision-making [15] [16].
- **Sentiment Analysis and Coaching Insights:** Vault CRM uses natural language processing (NLP) and embedded analytics to extract insights from rep-HCP interactions (e.g., emails, call summaries, meeting notes). These insights support real-time coaching, sentiment decoding, and post-engagement analysis—helping managers and reps improve message effectiveness and refine customer strategies [17] [18].
- **Voice-Activated CRM and Omnichannel Coordination:** With the planned introduction of CRM Voice, reps will be able to interact with Vault CRM using voice commands—powered by Apple Intelligence. This feature supports hands-free navigation, enabling more fluid engagement logging and daily workflow management in clinical and in-field environments [16].
- **Approved Content and Compliant Delivery:** Through integration with Vault Approved Email, Vault Engage, and Campaign Manager, reps can access pre-approved, modular content tailored to each HCP's consent status and therapeutic focus. These tools ensure regulatory compliance while enabling personalized content deployment across all channels [16].

3.3.2. Real-World Outcomes and Strategic Positioning

While Vault CRM's full AI suite is still in rollout, early customer insights from Veeva's 2025 Commercial Summit emphasize its alignment with field needs. Reps using Vault CRM report improved workflow satisfaction due to transparency, integrated content access, and streamlined coaching support [17].

Designed for flexibility and scalability, Vault CRM unifies omnichannel orchestration, AI-guided engagement, and modular configuration—all within a single cloud-native platform. As pharmaceutical organizations seek to replace legacy CRMs with more agile, field-aligned technologies, Veeva's product vision positions Vault CRM not merely as a software solution, but as an orchestration layer for the next generation of HCP engagement [19].

In summary, AI-enabled CRM platforms represent more than a digital upgrade—they are reshaping how life sciences organizations engage with healthcare professionals. By embedding intelligence into every stage of the engagement

process, these platforms enable scalable personalization, enhance cross-functional alignment, and shorten the path from data to action. As companies seek to meet rising HCP expectations and regulatory demands, intelligent CRM systems have become central to orchestrating timely, relevant, and compliant interactions—turning insight into measurable commercial impact.

4. Real-World Case Studies of AI-Driven Innovation in Life Sciences

Artificial intelligence is rapidly becoming a cornerstone of transformation in the life sciences industry. While the primary focus of AI applications remains in research-intensive domains such as drug discovery, clinical trial design, and biomarker identification, leading pharmaceutical companies are increasingly extending these capabilities into commercial operations [40].

The following case studies illustrate how AI-driven innovation is enabling smarter decision-making, operational agility, and more personalized engagement with healthcare professionals (HCPs). These real-world examples highlight the expanding strategic value of AI in shaping the future of customer engagement across life sciences.

4.1. Sanofi: Enterprise-Scale AI Enablement Through Plai

Sanofi represents a compelling example of enterprise-wide digital transformation through artificial intelligence (AI). Its proprietary Plai platform serves as an integrated AI orchestration layer that supports data-driven decision-making across research and development (R&D), manufacturing, supply chain, and, increasingly, commercial functions [20].

Plai, developed in collaboration with Aily Labs, enables real-time simulation and business scenario testing through a conversational interface known as Plai Concierge. By mid-2024, Sanofi employees had initiated over 1.4 million interactions with the platform—an indicator of significant internal adoption [21]. The platform synthesizes cross-functional data to support forecasting, performance modeling, and resource allocation [20].

In its most mature applications, Plai has improved predictive supply chain analytics, with AI models capable of identifying 80% of low-inventory risks in advance [20]. The same architecture underpins the Commercial AI Accelerator, which is tasked with redesigning engagement strategies, sales operations, and incentive systems using AI. While specific commercial outcomes are not yet publicly disclosed, Sanofi has stated its intent to leverage Plai in transforming field execution and omnichannel outreach [21] [22].

Sanofi's Responsible AI framework provides a foundation for expanding Plai into external-facing functions. The framework includes principles for explainability, transparency, and compliance—critical for scaling AI across regulated HCP engagement activities [36].

As such, Sanofi's Plai program exemplifies how AI-driven orchestration is evolving from internal operations to external engagement, positioning the company as a leader in strategic AI enablement within life sciences.

4.2. Novartis: AI-Driven Next-Best-Action (NBA) in HCP Engagement

Novartis is actively embedding artificial intelligence (AI) into its enterprise workflows, expanding from its early applications in drug discovery toward commercial optimization and healthcare professional (HCP) engagement. At the core of this shift is a strategic investment in next-best-action (NBA) systems designed to support field execution and omnichannel engagement [37].

Novartis emphasizes ethical AI deployment with clear principles around fairness, transparency, and human oversight [37]. The company has developed internal AI tools for sales forecasting, marketing mix modeling, and dynamic engagement planning—laying the groundwork for more responsive and tailored HCP interactions [38].

AI-driven engines, such as the internal "Buying Engine" and "AI Nurse," are helping personalize field outreach and identify the most effective engagement tactics, using behavioral and transactional data as inputs [38].These efforts are further supported by new leadership roles focused on integrated field targeting and NBA orchestration—signaling the company's commitment to scaling AI in customer-facing functions [39].

While Novartis's AI-enabled engagement models are still evolving, they represent a deliberate pivot from static sales strategies toward adaptive, data-informed decision-making—positioning the company at the forefront of responsible and scalable AI transformation in life sciences.

4.3. Pfizer: Dual-Track AI Strategy for Medical Information and Marketing Optimization

Pfizer is strategically deploying artificial intelligence (AI) to enhance both patient interaction and HCP-facing marketing operations. Two flagship initiatives illustrate its approach: a suite of medical information chatbots (Medibot, Fabi, Maibo) and the generative AI–based marketing platform known as Charlie [23] [24] [25].

4.3.1. AI-Powered Chatbots for Medical Information

To meet the demand for timely, compliant medical information, Pfizer developed AI chatbots tailored to regional markets—Medibot in the U.S., Fabi in Brazil, and Maibo in Japan. These digital agents are designed to respond to frequently asked questions using pre-approved content from Pfizer's global medical information databases. According to Pfizer, the bots can address more than 150 common queries and deliver consistent, regulatory-compliant responses 24/7 [23] [24].

These tools reduce call center volume while enhancing customer satisfaction by providing accurate information quickly and in local languages. Pfizer reported that the bots are used by both HCPs and patients seeking information on indications, dosages, or side effects [23] [24].

4.3.2. Charlie: Generative AI for Agile Pharma Marketing

Alongside its chatbot strategy, Pfizer launched Charlie in 2024—an internal generative AI platform created in partnership with Publicis Groupe. Charlie is designed to transform the pharma marketing content lifecycle, from copy generation to regulatory review [25].

Charlie's capabilities include copy refinement, compliance flagging, and audience targeting suggestions. It can tailor messages for HCPs or patients and align content with therapeutic context while reducing internal review time. The platform also provides automated risk scoring and prioritizes legal review queues—streamlining content approvals and shortening campaign activation cycles [26].

5. Challenges & Barriers to AI Implementation

Despite the promise of artificial intelligence in transforming customer engagement, its successful deployment in the pharmaceutical industry remains fraught with challenges. These barriers span technical, organizational, regulatory, and ethical dimensions, often limiting the effectiveness of AI-powered solutions.

One of the most pressing issues is data fragmentation and poor interoperability across systems. While CRM platforms accumulate large volumes of HCP interaction data, their inability to synchronize in real time with other marketing, sales, and medical systems often results in siloed insights that are not actionable [41]. CRM systems are frequently underutilized in pharma—despite capturing a wealth of data, they fail to inform actionable strategies due to lack of real-time integration and insight delivery [41].

Another significant barrier is the lack of transparency and explainability of AI models. When recommendations—such as Next-Best-Actions or predictive HCP segmentation—are generated by opaque algorithms, commercial teams may be reluctant to trust or adopt them. This undermines AI's integration into field operations and strategic planning. Limited explainability of model outputs and unclear accountability frameworks hamper AI's acceptance, especially in regulated environments where justification of decisions is critical [41].

Additionally, bias and fairness concerns emerge when AI systems are trained on non-representative or limited datasets. Skewed training data can perpetuate discriminatory patterns in HCP targeting or content delivery, thereby reducing trust and compromising equity [41]. Overfitting is another experimental weakness—AI models may perform well on training data but fail to generalize to unseen data, resulting in flawed recommendations or inaccurate predictions [41].

Ethical concerns also arise in relation to data privacy, patient consent, and responsible use of personal health information. As AI systems increasingly rely on large-scale health and behavioral data, ensuring secure, ethical, and transparent usage becomes critical. Regulatory frameworks often lag behind technological advancements, creating uncertainty around compliance and governance [41]. The complexity of deep learning models further adds to these challenges, as many AI systems function as 'black boxes'—making it difficult for users to interpret or audit the rationale behind decisions [41].

Organizational resistance and cultural inertia remain non-trivial obstacles. Many pharmaceutical companies are still transitioning from legacy systems and traditional commercial models, making it difficult to embed AI into workflows and decision-making processes. While the technical infrastructure for AI exists, its impact is diluted when companies fail to align cross-functional teams and leadership around a unified digital vision [40].

Concerns over intellectual property rights and workforce displacement also contribute to hesitancy. As AI begins to generate novel insights and streamline decision-making, questions arise around the ownership of AI-generated content and its implications for traditional roles in sales and marketing [41].

These multifaceted challenges underscore that AI's success in customer engagement is not purely a matter of technology. It requires strategic alignment, trust-building among commercial teams, robust data infrastructure, and a strong governance framework to ensure safe, compliant, and meaningful use.

6. Conclusion

Artificial intelligence is redefining the architecture of customer engagement in the life sciences industry. As demonstrated throughout this paper, AI-enabled CRM platforms—such as IQVIA OCE+, Salesforce Life Sciences Cloud, and Veeva Vault CRM—are not merely enhancing legacy systems; they are catalyzing a fundamental transformation. By embedding predictive analytics, next-best-action engines, and real-time orchestration into omnichannel workflows, these platforms enable organizations to shift from fragmented outreach to cohesive, insight-driven strategies.

Case studies of Sanofi, Novartis, and Pfizer illustrate how AI is being operationalized beyond R&D to build agile, personalized, and scalable commercial operations. These examples underscore a pivotal shift: AI has moved from the periphery to the strategic core of customer engagement, enabling life sciences firms to achieve both customer-centricity and competitive differentiation in a highly regulated, digitally complex environment.

However, the path forward is layered with challenges. Data fragmentation, algorithmic opacity, and limited cross-functional integration remain persistent barriers. Moreover, as AI-powered engagement becomes increasingly autonomous and generative in nature, the demand for transparent, ethical governance will only intensify. Ensuring that AI augments—rather than replaces—human judgment is crucial to sustaining trust and adoption.

Looking ahead, the next frontier of transformation includes the convergence of patient- and HCP-facing AI tools, the integration of generative AI into compliant content development pipelines, and the institutionalization of ethical AI frameworks as standard practice. These advancements will further elevate the strategic role of AI in orchestrating adaptive, real-time engagement across the pharmaceutical value chain.

Ultimately, the long-term value of AI lies not just in automation or efficiency, but in its capacity to close the loop between data, decision, and action—at scale. For life sciences organizations ready to invest in robust infrastructure and ethical deployment, AI presents a pathway to a reimagined engagement model: one that is anticipatory, responsive, and deeply aligned with the needs of healthcare professionals and the patients they serve.

References

[1] IQVIA. A midsize life sciences company optimized field deployment with AI and real-world data [Internet]. IQVIA; 2023 [cited 2025 May 27]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/case-studies/cs---ce---oce-plus-case-study---aug-2023.pdf

[2] Graphite Digital. Disconnected pharma: Navigating digital challenges and priorities [Internet]. Graphite Digital; 2024 [cited 2025 May 27]. Available from: https://www.graphitedigital.com/downloads/disconnected-pharma

[3] McKinsey & Company. Closing the digital gap in pharma [Internet]. McKinsey & Company; 2016 [cited 2025 May 27]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/closing-the-digital-gap-in-pharma

[4] Flaiz W. AI in pharmaceutical CRM: Transforming data analysis & engagement. White paper. 2025. Available from: https://www.williamflaiz.com/blog/ai-in-crm-data-analysis-a-pharmaceutical-industry-perspective

[5] McKinsey & Company. Generative AI in the pharmaceutical industry: Moving from hype to reality [Internet]. McKinsey Global Institute; 2024 [cited 2025 May 27]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality

[6] Abomusallam A. Digital customer engagement: how can pharmaceutical organizations create better value? [PhD dissertation]. Coventry, UK: University of Warwick; 2023. Available from: Digital customer engagement: how can pharmaceutical organizations create better value? - WRAP: Warwick Research Archive Portal

[7] Deloitte. Future of customer engagement in pharma [Internet]. Deloitte Centre for Health Solutions; 2024 [cited 2025 May 27]. Available from: https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/analysis/unlocking-the-future-of-customer-engagement-in-pharma.html

[8] IQVIA. Modern CRM applications for the life sciences industry [Internet]. IQVIA; 2023 [cited 2025 May 27]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/publications/gartner-crm-report-executive-brief.pdf

[9] IQVIA. Customer engagement in the era of unlimited data and artificial intelligence [Internet]. IQVIA; 2024 [cited 2025 May 27]. Available from: https://www.iqvia.com/locations/emea/library/white-papers/customer-engagement-in-the-era-of-unlimited-data-and-artificial-intelligence

[10] ZS Associates. Generative AI for life sciences and pharma marketing [Internet]. ZS Associates; 2024 [cited 2025 May 27]. Available from: https://www.zs.com/insights/generative-ai-in-life-sciences-marketing

[11] IQVIA. At the cutting edge: The rise of AI and technology-enhanced customer engagement in the life sciences industry [Internet]. IQVIA; 2023 [cited 2025 May 27]. Available from: https://www.iqvia.com/library/white-papers/the-rise-of-ai-and-technology-enhanced-customer-engagement-in-the-life-science-industry

[12] Salesforce. Salesforce Life Sciences Cloud Newsroom overview [Internet]. Salesforce; 2024 [cited 2025 May 27]. Available from: https://www.salesforce.com/news/stories/life-sciences-cloud-news

[13] Salesforce. Salesforce Life Sciences Cloud Demo Video [Internet]. Salesforce; 2024 [cited 2025 May 27]. Available from: https://www.salesforce.com/resources/videos/lifesciences-cloud-demo

[14] Salesforce. Salesforce and Takeda Partnership Press Release [Internet]. Salesforce; 2025 May 19 [cited 2025 May 27]. Available from: https://www.salesforce.com/news/press-releases/2025/05/19/takeda-life-sciences-cloud-customer-engagement

[15] Veeva Systems. Announcing Veeva AI [Internet]. Veeva; 2023 [cited 2025 May 27]. Available from: https://www.veeva.com/resources/announcing-veeva-ai/

[16] Veeva Systems. Vault CRM features brief [Internet]. Veeva; 2025 [cited 2025 May 27]. Available from: https://www.veeva.com/resources/veeva-vault-crm-features-brief/

[17] Veeva Systems. Veeva Commercial Summit 2025: AI Integration in Vault CRM [Internet]. Veeva; 2025 [cited 2025 May 27]. Available from: https://www.veeva.com/resources/veeva-ai-2025-veeva-commercial-summit-opening-keynote/

[18] Veeva Systems. Field-driven customer journeys [Internet]. Veeva; 2025 [cited 2025 May 27]. Available from: https://www.veeva.com/wp-content/uploads/2023/06/Thought-Starter-Series_Field-Driven-Customer-Journeys_NA.pdf

[19] Veeva Systems. The future of engagement in biopharma [Internet]. Veeva; 2024 [cited 2025 May 27]. Available from: https://www.veeva.com/resources/the-future-of-customer-engagement-in-biopharma/

[20] Sanofi. Exploring our digital transformation strategies and innovations [Internet]. Sanofi; 2023 [cited 2025 May 27]. Available from: https://www.sanofi.com/en/magazine/our-science/exploring-our-digital-transformation-strategies-and-innovations

[21] Sanofi. Annual general meeting presentation deck [Internet]. Sanofi; 2025 [cited 2025 May 27]. Available from: https://www.sanofi.com/en/investors/financial-results-and-events/general-meetings/annual-general-meeting-2025

[22] Sanofi. Partner spotlight: Owkin and Sanofi embrace precision medicine with AI [Internet]. Sanofi; 2023 [cited 2025 May 27]. Available from: https://www.sanofi.com/en/magazine/our-science/partner-spotlight-owkin-and-sanofi-embrace-the-golden-era-of-precision-medicine-with-ai

[23] Pfizer. The bot will chat with you now [Internet]. Pfizer; 2019 [cited 2025 May 27]. Available from: https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2019/our-bold-moves/win-the-digital-race-in-pharma/the-bot-will-chat-with-you-now/index.html

[24] Pfizer. Meet the new digital assistants [Internet]. Pfizer; n.d. [cited 2025 May 27]. Available from: https://www.pfizer.com/news/articles/meet_the_new_digital_assistants_transforming_patient_medical_information

[25] Swant M. With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing [Internet]. Digiday; 2024 Feb 22 [cited 2025 May 27]. Available from: https://digiday.com/marketing/with-charlie-pfizer-is-building-a-new-generative-ai-platform-for-pharma-marketing/

[26] Mad About Marketing. Pfizer's game-changing AI platform [Internet]. 2024 Feb 22 [cited 2025 May 27]. Available from: https://madaboutmarketing.com/news/pfizers-game-changing-ai-charlie-platform-revolutionizing-pharma-marketing-ai-technology/

[27] Accenture. Reinventing life sciences in the age of Gen AI [Internet]. Accenture; 2024 [cited 2025 May 27]. Available from: https://www.accenture.com/content/dam/accenture/final/industry/life-sciences/document/Accenture-POV-Reinventing-Life-Sciences-Age-of-Gen-AI-28Aug2024.pdf

[28] Frost & Sullivan. Healthcare & Life Sciences 2025: Technology, transformation, and growth [Internet]. Frost & Sullivan; 2025 [cited 2025 May 27]. Available from: https://www.frost.com/growth-opportunity-news/healthcare/healthcare-it/healthcare-life-sciences-2025-the-future-of-technology-transformation-and-growth-tjstory-cim-sg/

[29] SG Analytics. The future of AI in customer engagement strategies [Internet]. SG Analytics; 2024 [cited 2025 May 27]. Available from: https://www.sganalytics.com/blog/future-of-ai-in-customer-engagement-strategies/

[30] ZS Associates. Life sciences leaders customer engagement 2025 [Internet]. ZS Associates; 2024 [cited 2025 May 27]. Available from: https://www.zs.com/insights/life-sciences-leaders-customer-engagement-2025

[31] IQVIA. IQVIA empowers orchestrated customer engagement with its next best artificial intelligence engine [Internet]. IQVIA; 2022 [cited 2025 May 27]. Available from: https://www.iqvia.com/library/brochures/iqvia-empowers-orchestrated-customer-engagement-with-its-next-best-artificial-intelligence-engine

[32] IQVIA. Rapid Rollout of IQVIA Next Best Delivers Immediate Boost in Sales Performance [Internet]. IQVIA; 2021 [cited 2025 May 27]. Available from: https://www.iqvia.com/library/case-studies/cs-next-best-boosting-sales-performance

[33] IQVIA. IQVIA Alerts reduced Sales Reps' lead to engagement time from 5 weeks to 48 hours with daily triggers [Internet]. IQVIA; 2025 [cited 2025 May 27]. Available from: https://www.iqvia.com/library/case-studies/iqvia-alerts-reduced-sales-reps-lead-to-engagement

[34] IQVIA. Accelerate Commercial Content Creation, Review & Distribution [Internet]. IQVIA; 2025 [cited 2025 May 27]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/fact-sheets/accelerate-commercial-content-creation-review-distribution.pdf

[35] Salesforce. MedTech Innovation on Life Sciences Cloud [Internet]. Salesforce; 2025 [cited 2025 May 27]. Available from:https://www.salesforce.com/en-us/wp-content/uploads/sites/4/Life-Sciences-Cloud_MedTech-Datasheet_FY26.pdf

[36] Sanofi. Responsible AI Guiding Principles [Internet]. [cited 2025 May 27]. Available from: https://www.sanofi.com/assets/dotcom/pages/docs/our-science/digital/ai-across-sanofi/en-responsible-ai-guiding-principles.pdf?trk=public_post_comment-text

[37] Novartis. Our commitment to ethical and responsible use of Artificial Intelligence (AI) [Internet]. [cited 2025 May 27]. Available from: https://www.novartis.com/esg/ethics-risk-and-compliance/compliance/our-commitment-ethical-and-responsible-use-artificial-intelligence-ai

[38] Novartis. From black holes to AI driven drug discovery – collaboration wins the day [Internet]. Novartis; 2024 [cited 2025 May 27]. Available from: https://www.novartis.com/stories/from-black-holes-ai-driven-drug-discovery-collaboration-wins-day

[39] Novartis Careers. (2024). Global Director, Integrated Field Targeting and NBA – Job Posting. Novartis; 2025 [cited 2025 May 27]. Available from: https://www.novartis.com/careers/career-search/job/details/req-10047118-director-integrated-field-targeting-and-nba-1-2

[40] Suri, G., Kaur, G., & Shinde, D. (2024). Beyond boundaries: exploring the transformative power of AI in pharmaceuticals. Discover Artificial Intelligence, 4, Article 82. 2024 [cited 2025 May 27]. Available from: https://doi.org/10.1007/s44163-024-00192-7

[41] R.S. Tade, S.N. Jain, J.T. Satyavijay, et al. Artificial intelligence in the paradigm shift of pharmaceutical sciences: a review. Nano Biomedicine and Engineering, 2023, 16(1): 64–77. [cited 2025 May 27]. Available from: http://doi.org/10.26599/NBE.2023.9290043